A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2016
At a glance
- Drugs Cediranib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Sep 2012 Planned end date changed from 1 Dec 2006 to 1 May 2013 as reported by ClinicalTrials.gov record.
- 13 Oct 2009 Planned number of patients changed from 12 to 37 as reported by ClinicalTrials.gov.